A study shows that a single infusion of CAR-T therapy cilta-cel can lead to at least five years of remission in about one-third of patients with relapsed or refractory multiple myeloma, suggesting potential curative outcomes for some patients.
Researchers at Emory University have presented exciting findings in the pursuit of an HIV cure. The study demonstrated the potential of Jak inhibitors, specifically ruxolitinib, to significantly decay the viral reservoir in people with HIV, offering a novel pathway toward long-term remission or a cure. The results showed an estimated 99.99% clearance of the peripheral HIV-1 reservoir in less than three years. The study also highlighted the impact of ruxolitinib on immune activation, cell survival, and immune dysregulation. While further research and clinical trials are needed, these findings offer hope for the development of cure-based interventions for HIV.